RET-altered Colon Cancer

1 clinical trials · Condition

Record	Firm	Date
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (NCT03037385)	Hoffmann-La Roche	2017-03-17

Every clearance here is in the API, with alerts when new ones post.